Brought to you by 
Serono licenses cancer candidate from Micromet
Dec 2004
Executive Summary
Micromet (antibody therapeutics for cancer, inflammation, and autoimmune conditions) and Serono SA have entered into an agreement to further develop Micromet's MT201 (adecatumumab), a fully human monoclonal antibody that targets the epithelial cell adhesion molecule (Ep-CAM) to fight various types of cancer.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Serono licenses cancer candidate from Micromet
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice